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INTRODUCTION
Glycohemoglobin (HbAlc) is most often used as
an intermediate indicator for blood glucose control
in diabetics, and the Diabetes Control and Compli-
cations Trial (DCCT) (1), United KingdomProspective
Diabetes Study (UKPDS) (2) and Kumamoto Study
(3) have greatly valued HbAlc as an indicator for
blood glucose control.
However, HbAlc levels are influenced by other
factors in addition to blood glucose. Of these other
factors, the life span of erythrocytes is particularly
important. Therefore, it appears reasonable to as-
sume that HbAlc levels fluctuate in patients with
chronic renal failure, particularly those on hemo-
dialysis (4, 5), because the life span of erythro-
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cytes changes due to periodic blood sampling, re-
sidual blood in the dialysis circuit, mechanical hemo-
lysis, erythropoietin administration and blood trans-
fusion (6).
In fact, it has been reported that HbAlc levels
tend to be low among hemodialysis patients, and
this tendency is particularly marked in patients on
erythropoietin therapy (7).
When assessing HbAlc, it is important to exam-
ine its relationship to past blood glucose levels and
to determine whether absolute HbAlc levels cor-
rectly represent diabetic control.
In each patient, a one-day seven-sample glucose
profile set (hereinafter referred to as profile set
mean blood glucose) was calculated by measuring
blood glucose levels on a total of seven occasions :
before and at 2 hours after each meal and at
bedtime. Profile set mean blood glucose was also
used in the DCCT (1), and when compared with
one-point blood glucose, it provides a more accu-
rate assessment of blood glucose control. There-
fore, we used profile set mean blood glucose as
the main indicator for blood glucose control and
compared HbAlc levels in diabetics with end-stage
renal disease (ESRD) with those in patients with-
out renal failure in an attempt to elucidate the ac-
curacy of HbAlc as an indicator for blood glucose
control in diabetics with ESRD. Furthermore, we
investigated the relationship between profile set
mean blood glucose and glycated albumin (GA),
which is unaffected by the life span of erythro-
cytes (8), in diabetics with ESRD, and then com-
pared absolute GA levels between diabetics with
ESRD and those with normal renal function.
MATERIALS AND METHODS
Subjects
A total of 86 diabetes patients with ESRD who
were admitted to our institution were divided into
two groups : 49 predialysis patients and 37 dialysis
patients. These 86 patients were compared to 40
diabetics with normal renal function (non-dialysis
patients). The 49 predialysis patients were patients
who would soon begin dialysis, while the 37 dialy-
sis patients were already on dialysis. Table 1 shows
the patient backgrounds, and while there were no
significant differences in average age among the
three groups, the average blood glucose levels in
the non-dialysis patients were higher than in the
predialysis or dialysis patients. In addition, except
for five predialysis patients, erythropoietin was
used in all ESRD patients.
Methods
Blood glucose levels were measured using a
quick blood glucose analyzer (GluTestAce : Sanwa
Kagaku K.K.) seven times a day (before and at 2
hours after each meal and at bedtime) to calculate
the profile set mean blood glucose. On the day
when the profile set mean blood glucose was de-
Table 1. Patient background
Cases
(n)
M/F
(n)
Mean age
(years)
Mean blood
glucose
(mg/dl)
BUN
(mg/dl)
Creatinine
(mg/dl)
Albumin
(g/dl)
ChE
(IU/dl)
Treatment
(Diet/Insulin/OHA)
(n)
Predialysis patients
with
end-stage renal disease
(n = 49)
36/13
63.9 ± 13.1
(37-90)
165.8± 47.8
(80 -313)
84.4 ± 29.8
(19.2-139.3)
8.2 ± 3.5
(2.1-20.8)
3.2 ± 0.6
(1.9-4.4)
3419± 1185
(1257-6209) 18/19/12
Dialysis patients
with
end-stage renal disease
(n = 37)
25/12
64.4 ± 11.1
(46 -86)
147.4 ± 38.8
(83 -233)
69.5 ± 23.8
(31.4-129.0)
9.7 ± 2.5
(5.6-16.3)
3.5 ± 0.4
(2.4-4.3)
3698 ± 1363
(1442-8163) 15/17/5
DM patients
with
normal renal function
(n = 40)
28/12
57.7 ± 14.4
(23-83)
228.9 ± 58.8
(140-367)
17.5 ± 6.6
(8.3-42.0)
0.9 ± 0.4
(0.3-2.6)
4.2 ± 0.3
(3.6-4.8)
5762 ± 1336
(3495-10373) 6/11/23
Mean ± SD
(min - max)
OHA : oral hypoglycemic agent
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termined, a blood sample was collected to meas-
ure HbAlc and GA by either the enzyme or HPLC
method using an automatic glycohemoglobin ana-
lyzer, an HLC-723 GHbV (Toso, Tokyo) and a bo-
ronic acid column (8). At the same time, reticulo-
cyte count (Ret) was determined using an ADVIA
120 (Bayer Medical, Tokyo) and erythrocyte cre-
atine level was measured using the method of Jiao
et al . (9). Three regression lines were calculated
for each patient group by simple regression where
HbA1c or GA was the response variable, and the
profile set mean blood glucose was the regressor
variable. Test for homogeneity of the three regression
slopes was conducted with a general linear model
using the profile set mean blood glucose, each
patient group, and the interaction of the profile set
mean blood glucose with each patient group. With
regard to statistical analyses, Mann-Whitney U test
and Fisher transformation were used, and p values
of <0.05 were considered significant.
RESULTS
Relationship between blood glucose control and
HbAlc in ESRD patients
Figure 1 shows the relationship between blood
glucose control and HbAlc in the predialysis, dialy-
sis and non-dialysis patients. The profile set mean
blood glucose was plotted against the horizontal axis,
and HbAlc was plotted against the vertical axis.
The coefficients of correlation(r) between blood glu-
cose control and HbA1c in the predialysis, dialysis
and non-dialysis patients were 0.47, 0.42 and 0.67,
respectively. While there were no marked differ-
ences in the y-intercept of the regression line
among the three groups, the slope of the regres-
sion line for the ESRD (predialysis and dialysis)
patients was shallower when compared with that
for the non-dialysis patients. A significant difference
(p=0.045) among the three regression slopes was
observed under analysis of variance.
This clearly shows that, in the ESRD patients,
the level of HbAlc was lower than indicated by their
profile set mean blood glucose.
The mean actual and corrected HbA1c levels for
the predialysis patients were 5.4±1.1 and 7.9±
1.1%, respectively, while those for the dialysis pa-
tients were 5.6±1.0 and 7.5±0.9% respectively (p<
0.0001). The corrected HbA1c levels were calcu-
lated by applying the profile set mean blood glu-
cose of each ESRD patient to the regression for-
mula for the HbA1c of non-dialysis patients.The
mean actual and corrected HbA1c levels were the
mean of an individual value of each patient in the
group. There were significant differences between
the mean actual and corrected HbAlc levels for the
predialysis and dialysis patients.
Comparison of erythrocyte life span between the
ESRD and non-dialysis patients
Table 2 compares the reticulocyte count (Ret) and
erythrocyte creatine (Cr) between the ESRD and
non-dialysis patients. Cr and Ret, which indicate
the levels of immature erythrocytes, in the ESRD
(predialysis and dialysis) patients were higher
than those in the non-dialysis group.
Relationship between blood glucose control and
GA levels in the ESRD patients
Figure 2 shows the relationship between GA
levels, which are unaffected by the life span of
erythrocytes, and blood glucose control in the
ESRD (predialysis and dialysis) patients. In each
patient, the profile set mean blood glucose was
plotted against the horizontal axis, while GA was
plotted against the vertical axis. The coefficients of
correlation(r) between blood glucose control and
GA in the predialysis, dialysis and non-dialysis pa-
tients were 0.56, 0.50 and 0.68, respectively. There
was no significant difference among the three re-
gression slopes under analysis of variance.
There was no significant difference between the
actual and corrected GA levels for the dialysis
Figure 1 : Relationship between blood glucose control and
HbA1c in diabetes patients with end-stage renal disease : Com-
parison to diabetes patients with normal renal function. (white
circles, dotted line=predialysis patients (r=0.47, p<0.0005); black
circles, solid line=dialysis patients (r=0.42, p<0.01) ; white trian-
gles, broken line=DM patients with normal renal function (r=
0.67, p<0.0001).
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patients (21.3±4.4 vs. 23.0±3.0%), while the actual
GA levels were lower than the corrected GA levels
for the predialysis patients (19.0±5.3 vs. 24.4± 3.7%).
DISCUSSION
The results of the present study confirm that
HbAlc levels in ESRD patients are lower than indi-
cated by blood glucose control and are lower than
those of diabetes patients with normal renal func-
tion. This phenomenon was seen in ESRD patients
who would soon begin dialysis and those who
were already on dialysis. The differences between
the actual and corrected HbAlc levels (difference
from values in non-dialysis patients under the
same blood glucose control) for the predialysis
and dialysis patients were comparable, thus sug-
gesting that there is no marked difference in the
degree of decrease in HbAlc between these two
groups of patients.
Carbamylated hemoglobin levels increase in the
erythrocytes of ESRD patients, and in the ion-
exchange column method, it coelutes with HbAlc.
As a result, it has been reported that HbAlc levels
are high in ESRD patients (10,11). However, with
a more recent ion-exchange column method, it is
possible to separate carbamylated hemoglobin from
HbAlc. In the present study, HbAlc levels were
measured using the latest ion-exchange column
method, and they did not include any carbamylated
hemoglobin.
Needless to say, blood glucose is one of the
main determining factors of HbAlc, but the life
span of erythrocytes can also play a role. As shown
in Table 2, the immature erythrocyte ratio for the
ESRD patients was higher than in the non-dialysis
patients with normal renal function. While there
was no statistically significant difference in reticu-
locyte count, the erythrocyte creatine levels in the
ESRD patients were significantly higher. Jiao et al .
(9) and Takemoto et al . (12) reported high levels
of erythrocyte creatine and low HbAlc levels in im-
mature erythrocytes (9). Therefore, increased im-
mature erythrocyte ratio appears to be involved in
the low HbAlc levels seen in ESRD patients.
Increased immature erythrocyte ratio involves
increased erythrocyte destruction and hematopoi-
esis. In dialysis patients, erythrocytes are physi-
cally destroyed during dialysis, and this can stimu-
Table 2. Comparison of reticulocyte count (Ret) and erythrocyte creatine (Cr) in patients with end-stage renal disease and DM
patients with normal renal function
Patients
(n)
Hematocrit
(%)
Reticulocyte
(%)
Creatine in erythrocyte
(µmol/g.Hb)
Predialysis patients
(n = 49) 24.7 ± 4.9† 2.35 ± 1.05 1.64 ± 0.66*
Dialysis patients
(n = 37) 28.5 ± 5.0† 2.17 ± 1.25 2.17 ± 0.95†
DM patients with
normal renal function
(n = 40)
42.4 ± 4.4 1.83 ± 0.66 1.29 ± 0.32
＊ : vs. DM patients with normal renal function, p< 0.05 Mean±SD
† : vs. DM patients with normal renal function, p < 0.0001
Figure 2: Relationship between blood glucose control and GA
in diabetes patients with end-stage renal disease: Comparison to
diabetes patients with normal renal function. (white circles,
dotted line=predialysis patients (r=0.56, p<0.0001); black circles,
solid line=dialysis patients (r=0.50, p<0.0005); white triangles, broken
line=DM patients with normal renal function (r=0.68, p< 0.0001).
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late hematopoiesis, thus increasing the immature
erythrocyte ratio. However, the increased imma-
ture erythrocyte ratio in the dialysis patients may
not be the main factor mainly due to loss of eryth-
rocyte during dialysis procedure ; even in pre-
dialysis patients who had not been on dialysis, the
immature erythrocyte ratio was high, while HbAlc
levels were low.
Subsequently, the cause of the increased imma-
ture erythrocyte ratio and decreased HbAlc levels
in ESRD patients may be factors that are common
to the predialysis and dialysis patients, i.e., peri-
odic blood sampling, erythropoietin administration
and blood transfusion. In any case, when com-
pared with diabetes patients without renal dys-
function, levels of HbAlc in the patients with ESRD
were lower than indicated by their blood glucose
control.
How much do HbAlc levels decrease in patients
with ESRD? The average decrease for the pre-
dialysis and dialysis patients was 2.5 and 1.9%, re-
spectively. If HbAlc levels are low in all diabetics
with ESRD, then the levels of HbAlc can be cor-
rected using a correction formula. However, be-
cause there are individual differences in the imma-
ture erythrocyte ratio and various factors are in-
volved in low HbAlc levels, we believe that HbAlc
levels cannot be accurately corrected using a for-
mula.
In such cases, a blood glucose control indicator
that is unaffected by the life span of erythrocytes
to replace HbAlc is required. GA is an indicator of
blood glucose control that is unaffected by the life
span of erythrocytes.
The coefficients of correlation between blood
glucose control and HbA1c in the predialysis, di-
alysis and non-dialysis patients were not signifi-
cantly different from the corresponding values be-
tween blood glucose control and GA in the respec-
tive patients groups. We cannot determine which
is better than the other only on the basis of these
coefficients of correlation as an parameter for
blood glucose control. Another important charac-
ter of the parameter is the similarity of the regres-
sion lines plotted against blood glucose control
and HbA1c or GA among the groups on the y-
intercept and the slope. The slope of the regres-
sion lines plotted against blood glucose control
and HbA1c for the ESRD was shallower than that
for the non-dialysis patients, while the changes in
GA levels in relation to the profile set mean blood
glucose in the patients with ESRD matched those
in non-dialysis patients with normal renal function
as shown in Figure 2. Based on these findings, it
can be said that GA is a better indicator for blood
glucose control than HbA1c in diabetics with
ESRD.
However, in the predialysis patients, GA levels
were lower, probably because serum albumin lev-
els were low in some patients as a result of neph-
rosis. Among the patients with serum albumin
levels of 3.5 g/dl, the GA levels for ESRD pa-
tients were comparable to those of the non-dialysis
patients with normal renal function. Therefore, the
level of GA is low in ESRD patients with nephrosis
or ESRD patients on peritoneal dialysis because
albumin leaks into the peritoneal dialysis solution,
and as a result, GA is not a good indicator for
blood glucose control for these patients.
Assessing the blood glucose control of dialysis
patients based solely on HbAlc can lead to errone-
ous results, and in such cases, GA is a good substi-
tute for HbAlc.
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